2023-03-06 09:11:07 ET
- Inari Medical ( NASDAQ: NARI ) added ~5% pre-market Monday after a study indicated that the company’s FDA-cleared FlowTriever device cut the mortality risk by 90% in patients with high-risk pulmonary embolism.
- The FLAME study was a prospective study designed to evaluate interventional treatment in high-risk PE patients who typically have a mortality rate of 25-50%.
- According to Inari ( NARI ), the trial met the primary endpoint for the FlowTriever arm, which indicated a mortality rate of 1.9%, representing a 90% decline compared to the 29.5% mortality rate seen in those who received other therapies.
- The investigators ended the study early “due to overwhelmingly positive outcomes in the FlowTriever patients,” the company added.
- “The results of the trial will have an immediate impact on the treatment of high-risk PE patients and will ultimately change clinical practice guidelines for that population,” Inari’s ( NARI ) medical chief Thomas Tu remarked.
- Seeking Alpha contributor, Zach Bristow reaffirmed his Buy rating on the stock ahead of the readout.
For further details see:
Inari gains as FlowTriever cuts mortality risk by 90% in pulmonary embolism